343 related articles for article (PubMed ID: 36063818)
1. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study.
Shoji F; Yamashita T; Kinoshita F; Takamori S; Fujishita T; Toyozawa R; Ito K; Yamazaki K; Nakashima N; Okamoto T
BMJ Open; 2022 Jun; 12(6):e061674. PubMed ID: 35676015
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
Ren S; Feng L; Liu H; Mao Y; Yu Z
Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
[TBL] [Abstract][Full Text] [Related]
5. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer.
Nyein AF; Bari S; Hogue S; Zhao Y; Maller B; Sha S; Gomez MF; Rollison DE; Robinson LA
BMC Cancer; 2022 Jan; 22(1):101. PubMed ID: 35073876
[TBL] [Abstract][Full Text] [Related]
6. The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.
Duttagupta S; Hakozaki T; Routy B; Messaoudene M
Curr Oncol; 2023 Oct; 30(11):9406-9427. PubMed ID: 37999101
[TBL] [Abstract][Full Text] [Related]
7. Physiologic colonic uptake of
Cvetkovic L; Régis C; Richard C; Derosa L; Leblond A; Malo J; Messaoudene M; Desilets A; Belkaid W; Elkrief A; Routy B; Juneau D
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1550-1559. PubMed ID: 33128571
[TBL] [Abstract][Full Text] [Related]
8. The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer.
Katayama Y; Yamada T; Shimamoto T; Iwasaku M; Kaneko Y; Uchino J; Takayama K
Transl Lung Cancer Res; 2019 Dec; 8(6):847-853. PubMed ID: 32010563
[TBL] [Abstract][Full Text] [Related]
9. Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.
Weis TM; Hough S; Reddy HG; Daignault-Newton S; Kalemkerian GP
J Oncol Pharm Pract; 2020 Apr; 26(3):564-571. PubMed ID: 31238808
[TBL] [Abstract][Full Text] [Related]
10. Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
Chau J; Yadav M; Liu B; Furqan M; Dai Q; Shahi S; Gupta A; Mercer KN; Eastman E; Hejleh TA; Chan C; Weiner GJ; Cherwin C; Lee STM; Zhong C; Mangalam A; Zhang J
BMC Cancer; 2021 Jul; 21(1):808. PubMed ID: 34256732
[TBL] [Abstract][Full Text] [Related]
11. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
[TBL] [Abstract][Full Text] [Related]
12. Investigating efficacy of "microbiota modulation of the gut-lung Axis" combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial.
Xia Q; Chen G; Ren Y; Zheng T; Shen C; Li M; Chen X; Zhai H; Li Z; Xu J; Gu A; Jin M; Fan L
BMC Cancer; 2021 Jun; 21(1):721. PubMed ID: 34157996
[TBL] [Abstract][Full Text] [Related]
13. Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
Luo WC; Mei SQ; Huang ZJ; Chen ZH; Zhang YC; Yang MY; Liu JQ; Xu JY; Yang XR; Zhong RW; Tang LB; Yin LX; Deng Y; Peng YL; Lu C; Chen BL; Ke DX; Tu HY; Yang JJ; Xu CR; Wu YL; Zhou Q
J Transl Med; 2024 Apr; 22(1):326. PubMed ID: 38566102
[TBL] [Abstract][Full Text] [Related]
14. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
Thompson NA; Stewart GD; Welsh SJ; Doherty GJ; Robinson MJ; Neville BA; Vervier K; Harris SR; Adams DJ; Dalchau K; Bruce D; Demiris N; Lawley TD; Corrie PG
BMC Cancer; 2022 Jan; 22(1):99. PubMed ID: 35073853
[TBL] [Abstract][Full Text] [Related]
15. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
[TBL] [Abstract][Full Text] [Related]
16. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer.
Shoji F; Yamaguchi M; Okamoto M; Takamori S; Yamazaki K; Okamoto T; Maehara Y
Front Mol Biosci; 2022; 9():1040424. PubMed ID: 36353732
[TBL] [Abstract][Full Text] [Related]
18. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
Hakozaki T; Richard C; Elkrief A; Hosomi Y; Benlaïfaoui M; Mimpen I; Terrisse S; Derosa L; Zitvogel L; Routy B; Okuma Y
Cancer Immunol Res; 2020 Oct; 8(10):1243-1250. PubMed ID: 32847937
[TBL] [Abstract][Full Text] [Related]
19. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer.
Boesch M; Baty F; Albrich WC; Flatz L; Rodriguez R; Rothschild SI; Joerger M; Früh M; Brutsche MH
Oncoimmunology; 2021; 10(1):1988403. PubMed ID: 34912592
[TBL] [Abstract][Full Text] [Related]
20. Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy.
Sarkar J; Cortes Gomez E; Oba T; Chen H; Dy GK; Segal BH; Ernstoff MS; Ito F
World J Oncol; 2023 Jun; 14(3):178-187. PubMed ID: 37350807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
